Elisabeth Manville
May 25, 2012
Featured

New stent comes with low risk of complications for patients with and without diabetes

A new stent produced by Medtronic, Inc. has shown to perform strongly in coronary artery disease (CAD) patients with and without diabetes. The Resolute Integrity drug-eluting stent (DES) was approved by the US Food and Drug Administration in February. It is specifically designed to treat patients who suffer from diabetes in addition to CAD. People with diabetes have a two- to three-fold increased risk for CAD as well as increased risks of complications and death. The results of a clinical trial showed that with the Resolute DES, rates of cardiac death, heart attack, and the need for repeat procedures were low in both patients with and without diabetes -- 9.6 percent for those with and 7.1 percent for those without, despite the high-risk nature of CAD in the diabetes patient population.

Companies
1
0 Comments
Related Articles
Ann Conkle
Mar 1, 2012
Next step toward artificial pancreas from Medtronic
In a step toward the developing an artificial pancreas, Medtronic announced that the results of the in-clinic ASPIRE (Automation to... Read More
Ann Conkle
Apr 13, 2012
Medtronic initiates US drug-eluting Balloon study for peripheral artery disease
Medtronic, Inc. announced today the start of the IN.PACT SFA II study, the company’s first US clinical trial for its... Read More
Elisabeth Manville
May 16, 2012
Novel treatment for artery disease has advantages over conventional treatments
A new treatment for coronary and peripheral artery disease is superior to corresponding conventional treatments. Two IN.PACT drug-eluting balloons, produced... Read More